Literature DB >> 27359375

Human papilloma virus infection in HIV-infected women in Belgium: implications for prophylactic vaccines within this subpopulation.

Sonia Menon1, Rodolfo Rossi2, Ina Benoy2, Jean P Bogers1,3, Davy van den Broeck1,3.   

Abstract

Although high-risk (HR) human papilloma virus (HPV) infection is the primary causative factor for cervical squamous intraepithelial lesions and invasive cervical cancer, the epidemiology of potentially HR (pHR) and low-risk HPV still remains to be elucidated in HIV-infected women. In addition, the synergistic potential of the multiplicity of HPV infections harboured renders it difficult to model the impact of vaccines. This cross-sectional analysis of HIV-infected women explores the epidemiology of abnormal cytology, thereby profiling and pairing pHR/HR HPV genotypes. This cross-sectional analysis reports the findings of 593 HIV-infected women, who underwent a cytological examination and HPV genotyping. A logistic regression model was fitted to adjust for age and coinfection with pHR/HR HPV genotypes. In the 143 women with abnormal cytology, a multiple pHR/HR HPV genotype prevalence of 64.1% [95% confidence interval (CI): 44.6-57.6%] was observed. A combined prevalence of HPV 16 and HPV 18 of 29.6% (95% CI: 22.2-37.8%) was found. HPV 6 and HPV 66 were found in two cases of low-grade squamous intraepithelial lesions as stand-alone genotypes and HPV 53 in a high-grade squamous intraepithelial lesion case. Pairing involving HPV 31 with HPV 16 and HPV 58 was found in high-grade squamous intraepithelial lesion cases. Significant associations were observed between abnormal cytology, multiple HPV, HPV 39 and HPV 53 [adjusted odds ratio (aOR): 2.02; P=0.01; 95% CI: 1.2-3.5; aOR: 3.8; P=0.01; 95% CI: 1.4-10.7; and aOR: 0.5; P=0.03; 95% CI: 0.2-0.9, respectively]. Coinfection with pHR/HR HPV genotypes HPV 39 and 53 was significantly associated with abnormal cytology. Research into the imputed role of HPV 31 in pairings, low-risk and pHR HPV genotypes in HIV-infected women is warranted.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 27359375     DOI: 10.1097/CEJ.0000000000000271

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  4 in total

1.  Meta-synthesis and science mapping analysis of HIV/HPV co-infection: a global perspective with emphasis on Africa.

Authors:  Hope Onohuean; Eric O Aigbogun; Bright E Igere
Journal:  Global Health       Date:  2022-03-24       Impact factor: 4.185

2.  Multiple HPV infections in female sex workers in Western Kenya: implications for prophylactic vaccines within this sub population.

Authors:  Sonia Menon; Davy van den Broeck; Rodolfo Rossi; Emilomo Ogbe; Hillary Mabeya
Journal:  Infect Agent Cancer       Date:  2017-01-06       Impact factor: 2.965

3.  Prevalence and correlates of cervical HPV infection in a clinic-based sample of HIV-positive Hispanic women.

Authors:  A P Ortiz; V Tamayo; A Scorsone; M Soto-Salgado; I Febo; P Piovanetti; H L Venegas-Ríos; Y Yamamura; C Zorrilla
Journal:  Papillomavirus Res       Date:  2017-06-19

4.  Cervical Dysplasia, Infection, and Phylogeny of Human Papillomavirus in HIV-Infected and HIV-Uninfected Women at a Reproductive Health Clinic in Nairobi, Kenya.

Authors:  Agnes Omire; Nancy L M Budambula; Leah Kirumbi; Hillary Langat; Danvas Kerosi; Washingtone Ochieng; Raphael Lwembe
Journal:  Biomed Res Int       Date:  2020-06-16       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.